Anatibant (LF 16-0687; XY-2405) drochloride is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant drochloride binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant drochloride crosses the blood-brain barrier (BBB). Anatibant drochloride can be used in research on brain damage diseases.
References:
[1]. Klaus Zweckberger, et al. Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial pertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett. 2009 Apr 24;454(2):115-7.
[2]. D Pruneau, et al. Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology. 1999 Sep;43(2-3):187-94.